Printer Friendly

Browse Ruxolitinib topic

Articles

1-126 out of 126 article(s)
Title Author Type Date Words
Incyte Touts Positive Phase 3 REACH3 Study Data Published in NEJM for Ruxolitinib (Jakafi) in Chronic Graft-Versus-Host Disease. Jul 16, 2021 155
Incyte says 'positive' Phase 3 REACH3 study data published in NEJM. Jul 14, 2021 240
China Regulator Accepts Antengene IND Application for the Phase II Clinical Trial of Single-Agent Selinexor for the Treatment of Myelofibrosis. Jul 6, 2021 762
Incyte receives FDA approval of extension of NDA review period for Ruxolitinib Cream for atopic dermatitis. Jun 14, 2021 191
Incyte receives FDA approval of extension of NDA review period for Ruxolitinib Cream for atopic dermatitis. Jun 14, 2021 192
Constellation Pharmaceuticals announces posters on ongoing MANIFEST study. Jun 11, 2021 690
US FDA Has Extended the sNDA Review Period for Ruxolitinib in Chronic Graft-Versus-Host Disease. Jun 10, 2021 308
Incyte announces U.S. FDA has extended sNDA review. Jun 8, 2021 210
Vitiligo treatment options abound but consider patient goals. Dotinga, Randy Jun 1, 2021 877
Vitiligo treatment options abound but consider patient goals. Dotinga, Randy Jun 1, 2021 876
Incyte reports positive Phase 3 results for Ruxolitinib cream in vitiligo. Financial report May 17, 2021 217
Incyte reports Q1 EPS 67c, consensus 64c. Financial report May 4, 2021 156
Incyte Shows Results from the Phase 3 DEVENT Study Evaluating Ruxolitinib as a Treatment for Patients with COVID-19 Associated Acute Respiratory Distress Syndrome on Mechanical Ventilation. Clinical report Mar 19, 2021 724
Incyte says DEVENT study of Ruxolitinib did not meet primary endpoint. Mar 18, 2021 324
US FDA Accepts for Priority Review NDA for Ruxolitinib Cream for Atopic Dermatitis. Feb 19, 2021 726
Incyte Posts Loss For 2020 As Research & Development Costs Soar. Financial report Feb 9, 2021 327
Study Finds That Anti-Viral Enzymes Transform Stem Cells Into Leukemia. Feb 1, 2021 715
TOP 5: Pediatric dermatology stories of 2020. Bosworth, Ted Feb 1, 2021 1077
ATOPIC DERMATITIS: Chronic itch: IgE may contribute to acute flares. Jancin, Bruce Jan 1, 2021 858
Incyte partners with Cellenkos for CK0804 for treating patients with myelofibrosis. Dec 31, 2020 222
Incyte partners with Cellenkos for CK0804 for treating patients with myelofibrosis. Dec 31, 2020 226
Incyte, Cellenkos Enter into Global Development Collaboration Agreement for CK0804. Dec 30, 2020 576
Novartis' RUXCOVID trial of ruxolitinib shows failure in treating COVID-19 complications. Dec 14, 2020 227
Novartis' RUXCOVID trial of ruxolitinib shows failure in treating COVID-19 complications. Dec 14, 2020 231
Incyte Shows Disappointing Results of Phase 3 RUXCOVID Study of Ruxolitinib (Jakafi) as a Treatment for Patients with COVID-19 Associated Cytokine Storm. Clinical report Dec 14, 2020 417
Incyte, Novartis Drug Ruxolitinib Fails To Meet Endpoint In Covid-19. Dec 14, 2020 331
GLOBAL TOP NEWS SUMMARY: Hope Returns As Eu And UK Extend Talks. Dec 14, 2020 1798
Syndax Pharmaceuticals reveals updated data from axatilimab phase one trial. Dec 7, 2020 176
Syndax Pharmaceuticals reveals updated data from axatilimab phase one trial. Dec 7, 2020 180
Incyte announces pooled analysis evaluating ruxolitinib cream for dermatitis. Oct 29, 2020 163
Phase 1 Of.GvHD Clinical Trial Shows Positive Two-Year Results. Aug 10, 2020 613
Sierra Oncology reports Q2 EPS ($1.58), consensus ($1.63). Aug 6, 2020 203
\Rigel Pharmaceuticals Inc partners with ICL for trial to evaluate fostamatinib for treating COVID-19 pneumonia. Jul 15, 2020 215
\Rigel Pharmaceuticals Inc partners with ICL for trial to evaluate fostamatinib for treating COVID-19 pneumonia. Jul 15, 2020 219
Novartis supports COVID-19 response in PHL through donation. Jul 15, 2020 751
COVID-19 response in the Philippines: Novartis contributions. Jul 7, 2020 751
Transmission of Legionnaires' Disease through Toilet Flushing. Couturier, Jeanne; Ginevra, Christophe; Nesa, Didier; Adam, Marine; Gouot, Cyril; Descours, Ghislain Jul 1, 2020 1896
Ruxolitinib more effective than standard therapy in patients with steroid-refractory acute GVHD, EHA reports. Jun 12, 2020 238
Ruxolitinib more effective than standard therapy in patients with steroid-refractory acute GVHD, EHA reports. Jun 12, 2020 242
New topicals coming for pediatric atopic dermatitis. Jancin, Bruce Jun 1, 2020 785
Multiple therapies in advanced-stage development. Jancin, Bruce Jun 1, 2020 1581
Constellation Pharmaceuticals provides update of preliminary data for CPI-0610. May 14, 2020 500
AI VIVO Seeks Collaboration Partners to Progress Top-ranked COVID-19 Therapeutic Candidates. May 7, 2020 480
Constellation Pharmaceuticals reports Q1 EPS (61c), consensus (62c). Financial report May 6, 2020 184
New topicals are coming for pediatric atopic dermatitis. Jancin, Bruce May 1, 2020 756
Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD. Sobash, Philip T.; Guddati, Achuta K.; Kota, Vamsi Apr 30, 2020 1943
Pharmaxis cancer drug ready to start myelofibrosis phase 2 studies this year. Apr 29, 2020 740
Coronavirus research: who got the priority label from the government. Apr 24, 2020 462
Incyte says Phase 3 REACH2 study data published in NEJM. Clinical report Apr 22, 2020 285
Incyte initiates Phase 3 RUXCOVID study in COVID-19 treatment. Apr 17, 2020 190
Novartis, Incyte to initiate Jakavi study in severe COVID-19 patients. Apr 3, 2020 293
'Natural is not always good' when it comes to treatments. Craven, Jeff Apr 1, 2020 805
Constellation Pharmaceuticals reports Q4 EPS (69c), consensus (69c). Financial report Mar 10, 2020 269
Mesenchymal Stem Cells Attract Endothelial Progenitor Cells via a Positive Feedback Loop between CXCR2 and CXCR4. Tan, Yingyun; Shu, Linjing; Xu, Peng; Bai, Shi Dec 31, 2019 4721
The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling. Shanthi Rexaline Calendar Dec 7, 2019 1744
Vitiligo: First-ever RCT finds topical ruxolitinib beneficial. Jancin, Bruce Dec 1, 2019 702
Coexistence of Myeloid and Lymphoid Neoplasms: A Single-Center Experience. Bouchla, Anthi; Thomopoulos, Thomas; Papageorgiou, Sotirios; Tsirigotis, Panagiotis; Bazani, Efthymi Nov 30, 2019 3598
Hemorrhagic Shock Sensitized the Diaphragm to Ventilator-Induced Dysfunction through the Activation of IL-6/JAK/STAT Signaling-Mediated Autophagy in Rats. Zhang, Li-Juan; Ni, Shao-Zhou; Zhou, Xian-Long; Zhao, Yan Nov 30, 2019 5343
Natural Sesquiterpene Lactones Enhance Chemosensitivity of Tumor Cells through Redox Regulation of STAT3 Signaling. Butturini, Elena; de Prati, Alessandra Carcereri; Boriero, Diana; Mariotto, Sofia Nov 30, 2019 10948
Constellation Pharmaceuticals reports Q3 EPS (82c), consensus (83c). Financial report Nov 6, 2019 140
Constellation Pharmaceuticals reports Q3 EPS (82c), consensus (83c). Financial report Nov 6, 2019 140
Acceleron announces updated results from Phase 3 luspatercept trial. Nov 6, 2019 174
Constellation soars 110% after reporting new data from myelofibrosis trial. Nov 6, 2019 210
Celgene Corporation (NASDAQ: CELG). Oct 30, 2019 2404
Incyte reports Q3 EPS 83c, consensus 65c. Financial report Oct 29, 2019 129
Vitiligo Drug Market Size, Demand, Types & Trend Forecast By Application (Clinic, Hospital & Others); By Players (Aclaris Therapeutics & Arrien Pharmaceuticals) Report 2019: Radiant Insights, Inc. Report Oct 28, 2019 669
Celgene Corporation (NASDAQ: CELG). Oct 24, 2019 2446
Global Lichen Planus Pipeline Insights 2019. Oct 21, 2019 808
Incyte Touts Positive 52-Week Results from a Randomised Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo. Clinical report Oct 18, 2019 300
Celgene Corporation (NASDAQ: CELG). Oct 17, 2019 2403
Incyte announces results from Phase 3 REACH2 study of ruxolitinib. Oct 16, 2019 167
Incyte REACH2 wins on ORR, secondary endpoint data just as important,says Stifel. Oct 16, 2019 106
Incyte data enchances confidence in $500M opportunity, says Piper Jaffray. Oct 14, 2019 141
Incyte announces 52-week results from Phase 2 study of Ruxolitinib cream. Clinical report Oct 13, 2019 190
Celgene Corporation (NASDAQ: CELG). Oct 9, 2019 2219
Celgene Corporation (NASDAQ: CELG). Oct 2, 2019 2266
Recent progress in treatment might lead to cure. Bosworth, Ted Oct 1, 2019 727
Vitiligo Facts Your Doctor May Not Be Telling You. Darwin Malicdem Sep 27, 2019 486
Celgene Corporation (NASDAQ: CELG). Sep 25, 2019 2266
Celgene Corporation (NASDAQ: CELG). Sep 19, 2019 2224
Bronchiolitis Obliterans Syndrome Pipeline Insight Report 2019. Report Sep 17, 2019 813
Celgene Corporation (NASDAQ: CELG). Sep 12, 2019 2266
Celgene Corporation (NASDAQ: CELG). Sep 5, 2019 2266
Invasive Fungal Disease, Isavuconazole Treatment Failure, and Death in Acute Myeloid Leukemia Patients. Bellanger, Anne-Pauline; Berceanu, Ana; Scherer, Emeline; Desbrosses, Yohan; Daguindau, Etienne; Roc Sep 1, 2019 1301
Protein Kinases and Their Inhibitors in Pluripotent Stem Cell Fate Regulation. Lee, Jungwoon; Park, Young-Jun; Jung, Haiyoung Aug 31, 2019 7566
Da-Cheng-Qi Decoction Alleviates Intestinal Injury in Rats with Severe Acute Pancreatitis by Inhibiting the JAK2- STAT3 Signaling Pathway. Jin, Wenyin; Shen, Yinfeng Aug 31, 2019 10225
Celgene Corporation (NASDAQ: CELG) - U.S. FDA Approves INREBIC[R] (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis -- 16/8/2019. Aug 29, 2019 781
Celgene Corporation (NASDAQ: CELG). Aug 29, 2019 2223
US FDA approves Celgene's Inrebic. Aug 20, 2019 237
US FDA approves Celgene's Inrebic. Aug 20, 2019 233
Celgene Corporation (NASDAQ: CELG). Aug 20, 2019 2223
FDA Approves Treatment For Patients With Certain Types Of Myelofibrosis. Aug 16, 2019 602
Celgene Corporation (NASDAQ: CELG). Aug 13, 2019 2223
Celgene Corporation (NASDAQ: CELG). Aug 8, 2019 2223
FACIAL VITILIGO: Topical ruxolitinib aided repigmentation, in phase 2 study. Oakes, Kari Aug 1, 2019 808
Topical Therapies for Psoriasis: The Revolution in Vehicles, Combinations, and Novel Agents. Stein Gold, Linda F. Aug 1, 2019 1561
Atopic Dermatitis: New Research on Disease Course and Treatment. Silverberg, Jonathan I. Aug 1, 2019 1553
Celgene Corporation (NASDAQ: CELG). Jul 31, 2019 2223
Incyte reports Q2 EPS 76c, consensus 48c. Financial report Jul 30, 2019 149
Aclaris trading near cash levels after trial failure, says William Blair. Jun 27, 2019 157
Incyte Touts Positive Results from a Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo. Clinical report Jun 19, 2019 146
Geron reports two imetelstat data presentations at EHA Congress. Jun 17, 2019 660
Incyte announced results from Phase 2 study of Ruxolitinib cream in vitiligo. Jun 16, 2019 147
Celgene announces updated analysis of data from Phase 2 JAKARTA2 clinical study. Clinical report Jun 3, 2019 206
Constellation Pharmaceuticals announces presentation of MANIFEST data at ASCO. Jun 3, 2019 433
Incyte Corporation passes US FDA approval for Jakafi to treat steroid-refractory acute GVHD. May 27, 2019 268
Incyte Corporation passes US FDA approval for Jakafi to treat steroid-refractory acute GVHD. May 27, 2019 264
Constellation Pharmaceuticals to present data from MANIFEST trial at ASCO. May 16, 2019 389
Incyte announces abstracts featuring genomic profiling data for ASCO. May 16, 2019 210
Endocarditis following Consumption of Cereal Associated with Salmonella enterica Subtype Mbandaka Outbreak. Dickter, Jana K.; Cai, LiYing; Snyder, David S. Apr 30, 2019 3008
Incyte reports Q1 EPS 63c, consensus 40c. Financial report Apr 30, 2019 124
Aclaris Therapeutics announces issuance of patent for the use of ruxolitinib. Apr 24, 2019 125
Ruxolitinib for Therapy of Graft-versus-Host Disease. Neumann, Thomas; Schneidewind, Laila; Weigel, Martin; Plis, Andrzej; Vaizian, Rem; Schmidt, Christia Mar 31, 2019 2917
US FDA accepts Celgene's New Drug Application for Fedratinib. Mar 6, 2019 201
US FDA accepts Celgene's New Drug Application for Fedratinib. Mar 6, 2019 197
US FDA Grants Priority Review for Fedratinib New Drug Application in Myelofibrosis. Mar 6, 2019 793
FDA grants Priority Review for Celgene's NDA for fedratinib. Mar 5, 2019 175
Concert Pharmaceuticals Presents Interim CTP-543 Phase 2 Data in Alopecia Areata. Mar 4, 2019 821
Current approach to early gastrointestinal and liver complications of hematopoietic stem cell transplantation. Atilla, Erden; Atilla, Pinar Ataca; Seval, Guldane Cengiz; Bektas, Mehmet; Demirer, Taner Report Feb 1, 2019 7231
Current approach to early gastrointestinal and liver complications of hematopoietic stem cell transplantation. Atilla, Erden; Atilla, Pinar Ataca; Seval, Guldane Cengiz; Bektas, Mehmet; Demirer, Taner Feb 1, 2019 7184
POLICITEMIA VERA: PRESENTACION CLINICA, DIAGNOSTICO Y NUEVOS ABORDAJES TERAPEUTICOS. Correa Saavedra, Maria Antonia; Ruiz Mejia, Camilo Jul 1, 2018 5512
Takotsubo Cardiomyopathy Associated with Polycythemia Vera. Basnet, Sijan; Rajagopalan, Priya; Dhital, Rashmi; Tharu, Biswaraj Jan 1, 2018 2037
Life-Threatening Hypertriglyceridemia in a Patient on Ruxolitinib and Sirolimus for Chronic Graft-versus-Host Disease. Watson, Allison P.; Brunstein, Claudio G.; Holtan, Shernan G. Jan 1, 2018 1542
Chronic Lymphocytic Leukemia and Myelofibrosis. Darawshy, Fares; Ben-Yehuda, Arieh; Atlan, Karine; Rund, Deborah Jan 1, 2018 2936
Exploring the Mechanism of Danshen against Myelofibrosis by Network Pharmacology and Molecular Docking. Li, Jie; Ma, Xiaoran; Liu, Cun; Li, Huayao; Zhuang, Jing; Gao, Chundi; Zhou, Chao; Liu, Lijuan; Wang Jan 1, 2018 5679
Ruxolitinib-associated tuberculosis--a rare complication of a novel drug! Patil, Vinod R.; Chandrakala, S.; Wasekar, Nilesh P.; Jijina, Farah; Mohite, Aniket B. Case study Mar 1, 2017 1397

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |